Cirtec Medical Enhances Board with Chris Cleary Appointment

Cirtec Medical Welcomes Chris Cleary to Its Board
Cirtec Medical is thrilled to share that Chris Cleary has joined its Board of Directors. With over thirty years of rich experience in corporate development, especially in mergers, acquisitions, and venture investments, Chris is poised to make significant contributions. Currently the Chief Executive Officer of Biomergence Capital, he has spent a substantial part of his career at Medtronic, overseeing a global acquisition strategy that led to more than 35 acquisitions.
Impressive Track Record in MedTech
Chris's expertise shines through in his previous roles, particularly at Medtronic, where he played key roles in major transactions, including the monumental $50 billion acquisition of Covidien back in 2014. His adeptness at managing significant divestitures, like the $6 billion sale of Covidien’s medical supply assets to Cardinal Health, demonstrates his strategic acumen.
A Proven Leader in Corporate Development
Before his tenure at Medtronic, Chris had a successful stint as CEO of Alesia Capital Services and spent 18 years at GE Capital in senior roles related to mergers and acquisitions across North America, Europe, Asia, and Latin America. His extensive background in deal-making and market dynamics will be invaluable to Cirtec Medical.
Aligning with Cirtec Medical's Vision
Chris's profound experience in scaling MedTech platforms and navigating global markets aligns perfectly with Cirtec Medical's ambitions. As a board member, he will steer critical aspects like strategic mergers and acquisitions, bolster product portfolio strategies, and foster commercial growth initiatives. His insights will bridge innovation with practical execution, enhancing advisory capabilities on partnerships, regulatory strategies, and global supply chain enhancements.
Leadership's Excitement for the Appointment
Rich Relyea, a partner at 3i, expressed his enthusiasm, stating, "We are thrilled to welcome Chris Cleary to our Board. His strategic insights and profound experience in corporate development will be crucial as we strive to elevate Cirtec Medical's offerings. We are confident that he will accelerate our growth and enable us to achieve exceptional outcomes in the MedTech space."
Collaborative Future Ahead
Shar Matin, the CEO of Cirtec Medical, also shared his anticipation. "Having known Chris for years, I’m excited about working closely with him to propel Cirtec Medical into its next growth phase. His considerable expertise and shared vision enhance our confidence in tackling new strategic opportunities. Chris’s involvement will truly inform our next chapter of development and success,” he remarked.
Chris Cleary's Vision
Upon his appointment, Chris Cleary shared his enthusiasm about joining Cirtec Medical's Board, stating, "Joining Cirtec Medical’s Board is an honor. I have long respected the company’s commitment to innovating life-changing medical devices and look forward to contributing to its strategic direction while collaborating with the leadership to create lasting value for our customers, patients, and stakeholders."
About Cirtec Medical
Cirtec Medical stands at the forefront of design, development, and manufacturing of advanced Class II and III medical devices. The company specializes in active implant systems, interventional devices, and high-precision components. Since its inception in 1987, Cirtec Medical has meticulously developed its capabilities to collaborate effectively with customers, transforming innovative technologies into remarkable medical devices spanning various therapeutic fields, including cardiology, neurology, and orthopedics. With a robust foundation in precision component design and a vertically integrated approach across 11 facilities worldwide, Cirtec Medical aims to expedite market entry, mitigate risks, and enhance revenue for its partners.
For Media Inquiries:
Abby Kupka
Sr. Manager, Marketing
Cirtec Medical
abby.kupka@cirtecmed.com
(763) 235-8835
Frequently Asked Questions
What role will Chris Cleary play at Cirtec Medical?
Chris Cleary will serve on the Board of Directors, providing strategic guidance and insights based on his extensive experience in corporate development.
What is Cirtec Medical known for?
Cirtec Medical specializes in the design and manufacture of complex Class II and III medical devices, focusing on innovative solutions for various health challenges.
How does Chris Cleary's background benefit Cirtec Medical?
His rich experience in M&A and corporate strategy will help Cirtec navigate growth opportunities and strengthen its product portfolio.
What are Cirtec Medical's plans for growth?
The company aims to expand its market presence and enhance its operational capabilities, guided by insights from experienced board members like Chris Cleary.
How can stakeholders benefit from Chris Cleary's appointment?
Stakeholders can expect enhanced strategic direction and growth opportunities at Cirtec Medical, linked to Chris’s expertise in the MedTech field.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.